Vanda Pharmaceuticals (NASDAQ:VNDA) Downgraded by Zacks Research to Strong Sell

Posted by George Bondi on Oct 8th, 2026

Zacks Research lowered shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) from a hold rating to a strong sell rating in a report released on Tuesday,Zacks reports.

A number of other brokerages also recently commented on VNDA. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th. B. Riley Financial reiterated a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Finally, Oppenheimer began coverage on Vanda Pharmaceuticals in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price target for the company. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $13.08.

Read Our Latest Stock Report on VNDA

Vanda Pharmaceuticals Trading Up 0.9%

NASDAQ VNDA opened at $4.56 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.60 and a current ratio of 1.61. The company has a market capitalization of $275.70 million, a price-to-earnings ratio of -0.98 and a beta of 0.69. The company’s 50-day simple moving average is $5.15 and its two-hundred day simple moving average is $5.94. Vanda Pharmaceuticals has a one year low of $4.27 and a one year high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. The business had revenue of $50.53 million during the quarter, compared to the consensus estimate of $61.92 million. Equities analysts forecast that Vanda Pharmaceuticals will post -3.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of VNDA. State Street Corp lifted its position in Vanda Pharmaceuticals by 16.6% during the second quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock valued at $21,520,000 after acquiring an additional 500,843 shares during the last quarter. Syon Capital LLC acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth $125,000. Hsbc Holdings PLC increased its position in shares of Vanda Pharmaceuticals by 144.5% during the second quarter. Hsbc Holdings PLC now owns 94,988 shares of the biopharmaceutical company’s stock worth $579,000 after purchasing an additional 56,133 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $220,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $749,000. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

(Get Free Report)

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company was founded in 2003 and is headquartered in Washington, DC Its work centers on conditions involving sleep, circadian rhythms, and psychiatric health.

Vanda’s commercial products include Hetlioz (tasimelteon), a melatonin receptor agonist approved in the United States for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, and Fanapt (iloperidone), an atypical antipsychotic used to treat schizophrenia in adults.